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Invasive Fusariosis in Nonneutropenic Patients
Invasive fusariosis (IF) is a fungal disease that mostly affects patients with hematologic malig-
nancies or who have received hematopoietic cell 
transplants. These patients often have prolonged 
and profound neutropenia, low levels of T cells, or 
both (1,2). Despite advances in early diagnosis and 
treatment, IF remains associated with high morbid-
ity and death rates (3,4).
Most studies on this fungal disease have oc-
curred in North and South America (4–9). However, 
the epidemiology of IF in Europe has not been fully 
characterized; within Europe, most multicenter stud-
ies on IF have occurred in Italy and France (8,10–12). 
A multicenter study by the European Confederation 
of Medical Mycology reported 76 cases of IF during 
2007–2012 (13). Most (60%) of these IF cases occurred 
in Italy but none in Spain. Previous single-center 
studies in Europe have reported regional differences 
in the distribution of Fusarium species and their sus-
ceptibilities to antimicrobial drugs, highlighting the 
importance of monitoring local epidemiologic data 
(13–15). We characterized the epidemiology of IF in 
Spain using a retrospective observational study that 
examined the effects of clinical and etiologic charac-
teristics on outcomes in a cohort of 58 IF patients at 
hospitals in Spain.
Methods
We conducted this study in 18 hospitals in Spain, 8 of 
which belong to the Spanish Network for Research in 
Infectious Diseases, Instituto de Salud Carlos III, in Ma-
drid, Spain. The study was approved by Reina Sofía 
University Hospital Institutional Review Board (Córdo-
ba, Spain), which waived the need to obtain written in-
formed consent. During January 2000–December 2015, 
hospital staff reviewed microbiological and pathologic 
registries to identify cases of IF. Data were recorded in a 
password-protected, electronic clinical research file. We 
monitored the collected data for missing information, 
inconsistencies, and ambiguities; when necessary, we 
sent queries to the appropriate hospitals for clarification.
We conducted a blind review of reported cases 
of IF. In this study, we included only proven cases 
of IF according to the consensus definitions of in-
vasive fungal diseases established by the European 
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Invasive fusariosis (IF) is associated with severe neu-
tropenia in patients with concurrent hematologic condi-
tions. We conducted a retrospective observational study 
to characterize the epidemiology of IF in 18 Spanish hos-
pitals during 2000–2015. In that time, the frequency of 
IF in nonneutropenic patients increased from 0.08 cases 
per 100,000 admissions in 2000–2009 to 0.22 cases per 
100,000 admissions in 2010–2015. Nonneutropenic IF 
patients often had nonhematologic conditions, such as 
chronic cardiac or lung disease, rheumatoid arthritis, his-
tory of solid organ transplantation, or localized fusariosis. 
The 90-day death rate among nonneutropenic patients 
(28.6%) and patients with resolved neutropenia (38.1%) 
was similar. However, the death rate among patients with 
persistent neutropenia (91.3%) was significantly higher. 
We used a multivariate Cox regression analysis to char-
acterize risk factors for death: persistent neutropenia 
was the only risk factor for death, regardless of antifun-
gal therapy.
SYNOPSIS
Organization for Research and Treatment of Can-
cer and the Mycoses Study Group Education and 
Research Consortium (16,17). IF can be proven in 
4 ways: microscopic examination of a specimen 
obtained by needle aspiration or biopsy that docu-
ments hyphae and isolates Fusarium spp. in the same 
tissue; blood culture yielding Fusarium spp. along-
side signs consistent with an infectious disease pro-
cess; isolation of Fusarium spp. in a normally sterile 
site (excluding bronchoalveolar lavage fluid, a para-
nasal or mastoid sinus cavity specimen, and urine) 
with accompanying signs of infection; or amplifica-
tion and sequencing of Fusarium DNA in formalin-
fixed paraffin-embedded tissue (16,17).
The participating hospitals identified Fusarium 
isolates using genetic sequencing, matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry, or morphologic character-
istics. In addition, all biological samples available 
at the time of this retrospective study (i.e., Fusarium 
isolates and specimens for biopsies) were sent to the 
Mycology Reference Laboratory at the Instituto de 
Salud Carlos III for confirmatory genetic sequencing. 
The isolates were freeze-dried on potato agar slants 
on arrival and stored in distilled water. Molecular 
identification was based on the translation elongation 
factor 1α gene (18). Isolates were cultured in GYEP 
medium (0.3% yeast extract, 1.0% peptone; Francisco 
Soria Melguizo S.A., http://www.f-soria.es) with 
2.0% glucose (Sigma-Aldrich Inc., https://www.sig-
maaldrich.com) at 30°C for 24–48 h. Genomic DNA 
was isolated by using an extraction procedure de-
scribed previously (19). Internal transcribed spacer 
region and a portion of the translation elongation 
factor 1α gene region were amplified as previously 
described (20). Alignment results were obtained and 
edited using Lasergene MegAlign Pro software from 
DNASTAR, Inc. (https://www.dnastar.com). All 
sequences were compared with reference sequences 
from GenBank and MycoBank (https://www.myco-
bank.org) databases by using InfoQuest FP version 
4.50 software (Bio-Rad Laboratories, https://www.
bio-rad.com). We also used an in-house database of 
the Mycology Reference Laboratory. When only biop-
sy specimens were available, we used real-time PCR 
specific for Fusarium species as previously described 
(21). When identified cases did not have available 
isolates or biologic material for PCR, we reported the 
specific Fusarium species only if obtained by MALDI-
TOF mass spectrometry in conjunction with histopa-
thology. We reported the remaining IF cases in pa-
tients with compatible clinical signs and symptoms as 
caused by Fusarium spp.
We defined survival as the time between the date 
of diagnosis and death or end of follow-up care (i.e., 
90 days). We defined the date of diagnosis as the day 
of the first Fusarium-positive culture. We defined dis-
seminated fusariosis as the involvement of >1 non-
contiguous organ. We did not consider fungemia 
cases as disseminated disease unless >1 organ was 
involved (e.g., skin, lung, or sinuses) (3). We defined 
neutropenia as a blood neutrophil count <500 cells/
mm3 temporally related to the onset of fungal disease. 
We defined persistent neutropenia as cases with con-
tinued low neutrophil counts at the end of treatment 
or death. We defined resolution of neutropenia as a 
persistent recovery of blood neutrophil count >500/
mm3 as determined by available hospital records.
We calculated the incidence of IF using total ad-
missions in the participating hospitals as the denomi-
nator; we expressed the incidence as the number of 
cases per 100,000 admissions. For statistical purposes, 
we arbitrarily defined 2 time periods: 2000–2009 and 
2010–2015. We compared incidences between the dif-
ferent periods by χ2 test using WinPepi version 11.65 
(Brixton Health, http://www.brixtonhealth.com). 
We considered p<0.05 to be significant.
We collected variables describing patient demo-
graphic data, concurrent conditions, neutropenia, re-
ceipt of corticosteroids, clinical manifestations, diag-
nostic procedures, treatment, and outcome (i.e., 90-day 
survival). We compared categorical variables using χ2 
or 2-tailed Fisher exact test, and we compared continu-
ous variables using the Mann-Whitney U test. We con-
ducted all statistical tests with SPSS Statistics 16.0 (IBM 
Inc., https://www.ibm.com) and R version 3.5.0 (R 
Foundation for Statistical Computing, https://www.r-
project.org); we considered 2-sided p values <0.05 to 
be significant. We constructed unadjusted Kaplan–
Meier curves and compared them using the log-rank 
test. In addition, we evaluated factors associated with 
90-day survival. We evaluated the following variables 
by univariate and multivariable Cox regression analy-
ses: age, sex, age-adjusted Charlson comorbidity index 
(22), underlying disease, receipt of antifungals and 
corticosteroids in the previous 30 days, neutropenia 
at diagnosis of fusariosis and at the end of follow-up, 
clinical manifestations, and primary treatment (mono-
therapy with a lipid formulation of amphotericin B, 
monotherapy with voriconazole, or combination treat-
ment). We entered variables with p<0.1 by univariate 
analysis into the multivariate analysis; we included 
variables with p<0.05 by the multivariate analysis in 
the final model. We evaluated the prediction accuracy 
of the final Cox model using the area under the receiv-
er operating characteristic curve.
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Results
Incidence of IF
We identified 75 patients with Fusarium spp. iso-
lated from clinical samples at 18 hospitals in Spain 
(Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/27/1/19-0782-App1.pdf) during 2000–2015. 
We excluded 10 patients with superficial infections 
and 7 with probable cases. In this study, the overall in-
cidence of IF during 2000–2015 was 0.55 cases/100,000 
admissions, corresponding to 0.42 neutropenic and 
0.13 nonneutropenic patients/100,000 admissions 
(p<0.01). The overall incidence of IF was 0.40 cas-
es/100,000 admissions during 2000–2009 and 0.79 
cases/100,000 admissions during 2010–2015 (p<0.01). 
Among neutropenic patients, the incidence of IF in-
creased from 0.32 to 0.57 cases/100,000 admissions 
(p = 0.06). Among nonneutropenic patients, the inci-
dence of IF increased from 0.08 to 0.22 cases/100,000 
admissions (p = 0.05). We also determined the annual 
cumulative incidence curves for the 2 groups of pa-
tients (Appendix Figure 1).
Clinical Characteristics
We identified 58 cases of IF: 44 (75.9%) occurred in 
neutropenic patients and 14 (24.1%) in nonneutrope-
nic patients (Table 1). Most (59%) patients were male. 
The median age was 67 years (interquartile range 
[IQR] 38–19 years) in neutropenic patients and 45 
years (IQR 28–65 years) in nonneutropenic patients 
(p = 0.05). In total, 36.4% of neutropenic and 42.9% of 
nonneutropenic patients had received corticosteroid 
therapy in the previous 30 days (p = 0.66); 72.7% of 
neutropenic and 35.7% of nonneutropenic patients 
had received antifungal therapy in the previous 30 
days (p = 0.66). At the end of follow-up (i.e., 90 days 
after diagnosis), 23 (52.3%) neutropenic patients had 
persistent neutropenia.
In total, 41 (93.2%) neutropenic and 5 (35.7%) non-
neutropenic patients had hematologic malignancies 
(p<0.01). In the neutropenic patient group, the most 
common hematologic malignancies were acute my-
eloid leukemia (43.2%) and acute lymphoid leukemia 
(18.2%). The proportion of patients who had received 
hematopoietic stem cell transplants (HSCTs) was 25% 
(11/44; 8 allogeneic, 2 autologous, and 1 cord blood 
haploidentical) in neutropenic patients versus 21.4% 
(3/14; 1 allogeneic and 2 autologous) in nonneutrope-
nic patients (p = 1.00). Four (9.7%) neutropenic patients 
and 1 (7.1%) nonneutropenic patient had graft-versus-
host disease (p = 1.00). Overall, 21.4% of nonneutrope-
nic patients and 2.3% of neutropenic patients had a his-
tory of solid organ transplantation (p = 0.04). Finally, 
35.7% of nonneutropenic and 2.3% of neutropenic pa-
tients had other underlying conditions (p = 0.04). Five 
nonneutropenic patients had chronic cardiac disease, 
T-cell prolymphocytic leukemia, rheumatoid arthritis, 
chronic obstructive pulmonary disease, or infantile re-
spiratory distress syndrome; 1 neutropenic patient had 
hemophagocytic lymphohistiocytosis.
Neutropenic patients were more likely than non-
neutropenic patients to have a fever at the time of diag-
nosis (90.9% vs. 57.1%; p<0.01). Neutropenic patients 
also were more likely to have skin lesions (65.9% vs. 
21.4%; p<0.01). We did not observe a difference in the 
proportion of patients with lung involvement in the IF 
infection (72.7% of neutropenic vs. 64.3% of nonneu-
tropenic patients; p = 0.74). We also did not observe 
a difference in the rate of concurrent infections (56.8% 
of neutropenic vs. 42.9% of nonneutropenic patients; p 
= 0.36) (Appendix Table 2). Disseminated disease oc-
curred more frequently among neutropenic patients 
(79.5%) than nonneutropenic patients (28.6%; p<0.01). 
In contrast, localized forms of IF, especially localized 
pneumonia (6.8% of neutropenic patients vs. 35.7% of 
nonneutropenic patients; p = 0.02) and fungemia (6.8% 
of neutropenic patients vs. 28.6% of nonneutropenic 
patients; p = 0.05), were more common among non-
neutropenic patients. However, disseminated funge-
mia was more common among neutropenic than non-
neutropenic patients (45.7% vs. 25%; p = 0.03). Among 
neutropenic patients, skin lesions were more common 
in persons with disseminated IF (77.1%) than localized 
IF (22.2%; p = 0.004); lung involvement also was more 
common among those with disseminated IF (82.9% vs. 
33.3%; p = 0.007).
Nonneutropenic patients were more likely than 
neutropenic patients to have a diagnosis on the basis 
of positive culture alone (43.2% of neutropenic pa-
tients vs. 85.7% of nonneutropenic patients; p<0.01). 
Neutropenic patients were more likely to have a di-
agnosis on the basis of a positive culture and histopa-
thology (52.3%) than nonneutropenic patients (14.3%; 
p = 0.01).
Isolated Fusarium Species
Thirty-six patients (62.1%) received a species-level eti-
ologic diagnosis using molecular methods: 26 (44.8%) 
by genetic sequencing and 10 (17.2%) by MALDI-TOF 
mass spectrometry (Table 2). Among these patients, 
F. solani species complex (SC) was the most com-
mon (18/58; 31.0%), along with Gibberella fujikuroi SC 
(10/58; 17.2%), and F. oxysporum SC (5/58; 8.6%). The 
remaining 22 (37.9%) cases were identified as caused 
by Fusarium spp. Among disseminated infections, 
most (74.4%) were reported to species level; the most 
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common were F. solani SC (15/39; 38.5%), F. fukikuroi 
SC (8/39; 20.5%), and F. oxysporum SC (3/39; 7.7%). 
In the cohort, disseminated IF also was caused by 2 F. 
brachygibbosum infections and 1 F. dimerum SC infec-
tion. Most (63.2%) localized infections were caused by 
Fusarium spp. F. solani SC (2/39; 5.1%), F. fukikuroi SC 
(2/39; 5.1%), and F. oxysporum SC (3/39; 7.7%) were 
the most common etiologic agents.
Therapeutic Regimens
Overall, 62.1% of patients received monotherapy 
(29.3% azoles, 32.8% amphotericin B), 27.6% of 
30 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 1, January 2021
 
Table 1. Clinical characteristics of patients with invasive fusariosis, Spain, 2000–2015* 
Variables Total Nonneutropenic Neutropenic p value† 
Total 58 (100.0) 14 (100.0) 44 (100.0)  
Sex     
 M 34 (58.6) 8 (57.1) 26 (59.1) 0.9 
 F 24 (41.4) 6 (42.9) 18 (40.9) 0.9 
Median age, y (IQR) 51 (31–67) 67 (38–79) 45 (28–65) 0.05‡ 
Treatment history (previous 30 d)     
 Antifungal 37 (63.8) 5 (35.7) 32 (72.7) 0.01 
 Corticosteroid 22 (37.9) 6 (42.9) 16 (36.4) 0.66 
Persistent neutropenia 23 (39.7) 0 23 (52.3)  
Concurrent conditions     
 Hematologic malignancy 46 (79.3) 5 (35.7) 41 (93.2) <0.01§ 
  Acute myeloid leukemia 20 (34.5) 1 (7.1) 19 (43.2)  
  Acute lymphoid leukemia 8 (13.8) 0 8 (18.2)  
  Non-Hodgkin lymphoma 5 (8.6) 2 (14.3) 3 (6.8)  
  Aplastic anemia 4 (6.9) 0 4 (9.1)  
  Multiple myeloma 3 (5.2) 2 (14.3) 1 (2.3)  
  Myelodysplasia 2 (3.4) 0 2 (4.5)  
  Chronic lymphoid leukemia 2 (3.4) 0 2 (4.5)  
  Chronic myeloid leukemia 1 (1.7) 0 1 (2.3)  
  Hodgkin´s lymphoma 1 (1.7) 0 1 (2.3)  
 History of hematopoietic stem cell transplant 14 (24.1) 3 (21.4) 11 (25.0) 1.00§ 
  Allogenic 9 (15.5) 1 (7.1) 8 (18.2)  
  Autologous 4 (6.9) 2 (14.3) 2 (4.5)  
  Cord blood haploidentical 1 (1.7) 0 1 (2.3)  
 Graft-versus-host disease 5 (8.6) 1 (7.1) 4 (9.1) 1.00§ 
 Acute 3 (5.2) 0 3 (6.8)  
 Chronic 2 (3.4) 1 (7.1) 1 (2.3)  
 Solid tumor 2 (3.4) 1 (7.1) 1 (2.3) 0.43§ 
 History of solid organ transplant 4 (6.9) 3 (21.4) 1 (2.3) 0.04§ 
 Other¶ 10 (17.2) 5 (35.7) 1 (2.3) <0.01§ 
Clinical manifestations     
 Fever 48 (82.8) 8 (57.1) 40 (90.9) <0.01§ 
 Skin lesions 32 (55.2) 3 (21.4) 29 (65.9) <0.01 
 Lung involvement 41 (70.7) 9 (64.3) 32 (72.7) 0.74§ 
 Sinusitis 9 (15.5) 1 (7.1) 8 (18.2) 0.43§ 
 Blindness 4 (6.9) 0 4 (9.1) 0.56§ 
Concurrent infection 31 (53.4) 6 (42.9) 25 (56.8) 0.36 
 Bacterial 17 (29.3) 2 (14.3) 15 (34.1) 0.18§ 
 Fungal 4 (6.9) 1 (7.1) 4 (9.1) 0.56§ 
 Viral 6 (10.3) 3 (21.4) 3 (6.8) 0.15§ 
 Polymicrobial 4 (6.9) 1 (7.1) 3 (6.8) 1.00§ 
Type of fusariosis     
 Localized 19 (32.8) 10 (71.4) 9 (20.5) <0.01§ 
  Cutaneous, localized 3 (5.2) 1 (7.1) 2 (4.5) 1.00§ 
  Pneumonia 8 (13.8) 5 (35.7) 3 (6.8) 0.02§ 
  Sinusitis 1 (1.7) 0 1 (2.3) 1.00§ 
  Fungemia 7 (12.1) 4 (28.6) 3 (6.8) 0.05§ 
 Disseminated 39 (67.2) 4 (28.6) 35 (79.5) <0.01§ 
Diagnosis     
 Culture 31 (53.4) 12 (85.7) 19 (43.2) <0.01 
 Culture and histopathology 25 (43.1) 2 (14.3) 23 (52.3) 0.01 
 Histopathology 2 (3.4) 0 2 (4.5) 1.00 
*Values are no. (%), except where indicated. 
†p values obtained by 2 test, except where indicated.  
‡Determined by Mann-Whitney U test.  
§Determined by Fisher exact test.  
¶Other conditions reported include hemophagocytic lymphohistiocytosis, chronic cardiac disease, T-cell prolymphocytic leukemia, rheumatoid arthritis, 
chronic obstructive pulmonary disease, and infantile respiratory distress syndrome. 
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patients received combination therapy (e.g., azoles 
plus amphotericin B, mostly liposomal amphotericin 
B plus voriconazole), and 10.4% of patients did not re-
ceive an active treatment (3 patients were not treated, 
2 received empirical caspofungin, and 1 received em-
pirical micafungin) (Appendix Table 3). Nonneutro-
penic patients were more likely than neutropenic pa-
tients to receive voriconazole monotherapy (54.5% vs. 
85.7%; p<0.01). We did not observe a difference in the 
proportions of patients who were treated with am-
photericin B (36.4% of neutropenic patients vs. 21.4% 
of nonneutropenic patients; p = 0.35). Sixteen (36.4%) 
neutropenic patients received combination therapy: 
14 received a lipid formulation of amphotericin B 
plus voriconazole and 2 received amphotericin B plus 
posoconazole. No nonneutropenic patients received 
combination therapy.
Outcomes
By 90 days after diagnosis, 56.9% of all patients had 
died: 28.6% of nonneutropenic patients and 65.9% of 
patients with neutropenia at IF onset (p = 0.01). We 
analyzed these results using unadjusted Kaplan–
Meier survival graphs (Appendix Figure 2; p = 0.03 
by log-rank test). The death rate of nonneutropenic 
patients (28.6%) was similar to that of patients who 
had recovered from neutropenia (38.1%; p = 0.56) and 
both rates were significantly lower than among pa-
tients with persistent neutropenia (91.3%; p<0.01).
After 90 days, 66.7% of patients with localized 
and 36.8% with disseminated disease had died (p = 
0.03). Overall, 66.7% (2/3) of patients with localized 
disease of the skin/soft tissue, 50% (4/8) with lung 
involvement, and 14.3% (1/7) with fungemia died.
In the assessment of prognostic factors, we ana-
lyzed 50 IF patients who received active antifungal 
therapy. In univariate analysis, 90-day death risk was 
associated with neutropenia at onset of IF and persis-
tent neutropenia. Age, sex, age-adjusted Charlson co-
morbidity index, corticosteroid therapy in the previous 
30 days, administration of antifungal in the previous 
30 days, hematologic malignancy, history of HSCT, 
fungemia, disseminated disease, and the treatment 
type (i.e., monotherapy with a lipid formulation of am-
photericin B, monotherapy with azoles or combined 
therapy) were not associated with 90-day survival. In 
multivariate analysis, persistent neutropenia (hazard 
ratio [HR] 7.08, 95% CI 1.91–26.17; p<0.01) was signifi-
cantly associated with 90-day death risk (Table 3). We 
calculated adjusted Kaplan–Meier survival curves for 
the Cox regression model (Figure; area under the re-
ceiver operating characteristic curve = 0.83).
Discussion
We described 58 cases of invasive Fusarium infec-
tions at 18 hospitals in Spain during a 15-year period 
(2000–2015). During this time, IF incidence increased 
from 0.40 (2000–2009) to 0.79 (2010–2015) cases per 
100.000 admissions (p<0.01). Incidence of IF in neu-
tropenic patients increased from 0.32 to 0.57 cases 
per 100,000 admissions (p = 0.06). We observed a 
3-fold increase in the incidence of IF in nonneutro-
penic patients, from 0.08 to 0.22 cases per 100,000 
admissions (p = 0.05). This increase might have been 
caused by an increase in the at-risk population, en-
vironmental exposure to Fusarium conidia, the in-
creased use of antifungal prophylaxis, or a combina-
tion of these factors.
To date, the highest IF incidence rates world-
wide are in healthcare centers in Brazil. A cohort 
of HSCT recipients at hospitals in Brazil during 
1985–2001 had a 0.6% prevalence of IF (1). During 
2007–2009, ≈10 years later, a prospective multicenter 
study by Nucci et al. reported a 3.7% IF prevalence 
among allogeneic HSCT patients and 3.4% among 
patients with acute myeloid leukemia (7). That 
study also found a 1-year cumulative incidence of 
5.2% among those who had received an allogeneic 
HSCT and 3.8% among those with acute myeloid 
leukemia or myelodysplasia (7). A >10-fold increase, 
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Table 2. Distribution of isolated Fusarium species, Spain, 2000–2015* 
Species Total Localized Disseminated p value† 
Total 58 (100.0) 19 (100.0) 39 (100.0)  
F. solani SC 18 (31.0) 3 (15.8) 15 (38.5) 0.08‡ 
Gibberella fujikuroi SC 10 (17.2) 2 (10.5) 8 (20.5) 0.29 
F. proliferatum 6 (10.3) 0 6 (15.4) 0.08 
F. verticillioides 3 (5.2) 2 (10.5) 1 (2.6) 0.25 
F. fujikuroi 1 (1.7) 0 1 (2.6) 0.67 
F. oxysporum SC 5 (8.6) 2 (10.5) 3 (7.7) 0.53 
F. brachygibbosum 2 (3.4) 0 2 (5.1) 0.45 
F. dimerum SC 1 (1.7) 0 1 (2.6) 0.67 
Fusarium spp. 22 (37.9) 12 (63.2) 10 (25.6) <0.01 
*Values are no. (%), except where indicated. All identifications (except undefined Fusarium spp.) obtained by genetic sequencing or matrix-assisted laser 
desorption/ionisation time-of-flight mass spectometry. SC, species complex. 
†p values obtained by Fisher exact test, except where indicated.  
‡Determined by 2 test. 
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from 86 to 1,023 IF cases per 100,000 admissions, 
occurred among patients with hematologic ma-
lignancies at a healthcare center in Brazil from 
2000–2005 to 2006–2010 (5). In the United States, a 
prospective multicenter study conducted by the 
Transplant-Associated Infection Surveillance Net-
work during 2001–2006 reported a 1-year cumula-
tive incidence of up to 0.3% of non-Aspergillus mold 
infections (23). In Italy, a multicenter retrospective 
study reported a 0.2% incidence of IF among pa-
tients who had received an allogenic HSCT during 
1999–2003 (24).
In this cohort in Spain, IF occurred frequently 
in patients with hematologic conditions and in 
HSCT recipients. IF occurs almost entirely in mark-
edly immunosuppressed patients who usually are 
neutropenic; we identified IF in nonneutropenic 
patients, including patients with a history of solid 
organ transplants, chronic cardiac or lung disease, 
or rheumatoid arthritis. These findings are in agree-
ment with Park et al. (9), who studied 37 patients 
with IF and noted that 54.1% of IF patients were non-
neutropenic, 83.8% had hematologic malignancies, 
and 16.2% had history of solid organ transplantation 
(9). Thus, nonneutropenia and certain nonhemato-
logic conditions might not be uncommon among 
IF patients.
Lungs, the bloodstream, and the skin were the or-
gans most frequently affected by IF. Fusarium species 
produce aleuroconidia, yeastlike structures that can 
invade the bloodstream and might cause fungemia 
and metastatic skin lesions (25).
IF is associated with high death rates. This co-
hort had a 90-day death rate of 56.9%, similar to rates 
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Table 3. Univariate and multivariate Cox regression analyses for 90-day death rate in 50 patients treated for invasive fusariosis, Spain, 
2000–2015* 
Characteristic 
Unadjusted hazard ratio 
(95% CI) p value 
Adjusted hazard ratio 
(95% CI) p value 
Sex     
 M 1.08 (0.52–2.25) 0.84 0.87 (0.41–1.84) 0.87 
 F 0.93 (0.45-1.93) 0.84   
Median age, y (IQR) 1.00 (0.99–1.01) 0.94   
Charlson index 1.01 (0.86–1.20) 0.87 1.16 (0.96–1.40) 0.12 
Treatment history (previous 30 d)     
 Antifungal 1.83 (0.81–4.14) 0.15   
 Corticosteroid 0.69 (0.33–1.45) 0.33   
Neutropenia at onset 3.16 (0.95–10.44) 0.06   
Neutropenia at the end of follow-up     
 Nonneutropenia Referent  Referent  
 Recovery from neutropenia 1.47 (0.38–5.69) 0.58 1.91 (0.48–7.64) 0.35 
 Persistent neutropenia 5.62 (1.65–19.11) 0.006 9.27 (2.43–35.42) 0.001 
Hematologic malignancy 2.44 (0.74–8.06) 0.14   
History of hematopoietic stem cell transplant 1.39 (0.65–2.99) 0.4   
Fungemia 0.21 (0.03–1.54) 0.13   
Disseminated disease 1.90 (0.77–4.67) 0.16   
Antifungal therapy     
 Monotherapy with lipid formulation of amphotericin B 1.95 (0.92–4.12) 0.08   
 Monotherapy with azoles 0.47 (0.19–1.15) 0.10   
 Combined therapy 1.08 (0.50–2.33) 0.84   
*Area under the receiver operating characteristic curve for this model was 0.82. 
 
Figure. Adjusted Kaplan-Meier 
curves obtained from the stratified 
Cox regression model for 90-day 
survival in 50 patients treated for 
invasive fusariosis, Spain, 2000–
2015. HR, hazard ratio. 
Invasive Fusariosis in Nonneutropenic Patients
noted in other studies (3,4,12,26). The death rates of 
nonneutropenic and neutropenic patients who re-
covered from neutropenia were similar (28.6% of 
nonneutropenic patients vs. 38.1% of neutropenic 
patients; p = 0.56), consistent with previous reports 
that 70% of IF cases resolve when patients recover 
from neutropenia (27). In this cohort, patients with 
persistent neutropenia had a 91.3% death rate de-
spite antifungal therapy. Persistent neutropenia was 
the single most predictive prognostic factor in IF, 
consistent with previous reports (2).
Researchers must identify effective therapeutic 
strategies to improve the prognosis of IF patients 
with persistent neutropenia. The treatment practices 
observed in our study align with guidelines from the 
European Society of Clinical Microbiology and In-
fectious Diseases Fungal Infection Study Group and 
European Confederation of Medical Mycology (13). 
We examined the effects of different therapeutic reg-
imens on 90-day death rate. We found no differences 
in the outcome of patients treated with voriconazole 
and those receiving a lipid formulation of ampho-
tericin B. Combination therapy also was not associ-
ated with outcome, consistent with results from the 
largest study series conducted so far (3,12). How-
ever, these results must be interpreted with caution. 
Nucci et al. (3) found that patients receiving combi-
nation therapy had more severe disease (3), possibly 
influencing the clinician’s decision to administer 2 
drugs. In our study, no nonneutropenic patients re-
ceived combination therapy; further studies should 
examine the potential benefits of combination ther-
apy in nonneutropenic patients. Finally, because 
we observed similar clinical responses in patients 
treated with a lipid formulation of amphotericin B 
or voriconazole as monotherapies, clinicians might 
not need to rely on antifungal susceptibility tests to 
guide treatment. Most clinically relevant Fusarium 
isolates exhibit high minimal inhibitory concentra-
tions to most antifungals, including azoles, echino-
candins, and polyenes (28–30).
Our study is subject to the limitations of ret-
rospective observational studies. For example, the 
sample size was limited to the cases with available 
data. Despite being a multicenter study during a 15-
year period, the sample size might be insufficient 
to detect significant differences in some groups. 
Furthermore, clinicians might prescribe a more 
potent treatment regimen for patients with severe 
disease, possibly skewing our analysis of treatment 
outcomes. Although all IF cases in this retrospec-
tive study met standard criteria (16,17), we could 
not determine the causative species in every case. 
Thus, the Fusarium species was only reported when 
determined by genomic sequencing or MALDI-
TOF mass spectrometry, because these techniques 
have high agreement rates (89.8%–97.0%) (31–33). 
All remaining IF cases in our series were reported 
as Fusarium spp. We also were not able to culture 
all Fusarium isolates because of a lack of specimens, 
especially for cases occurring before 2010 in hospi-
tals in which Fusarium isolates were not collected as 
part of routine procedures
In conclusion, our data show that IF is an emerg-
ing infection in Spain. We report an increase in the 
incidence of IF among nonneutropenic patients, in-
cluding those with hematologic conditions and other 
concurrent conditions, such as chronic cardiac or lung 
diseases, rheumatoid arthritis, or history of solid or-
gan transplants. Our results support previous studies 
reporting that IF survival is critically dependent on 
resolution of neutropenia. 
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Appendix Table 1. Participating hospitals in study on invasive fusariosis, Spain, 2000–2015 
Hospital 
Hospital Universitario La Paz, Madrid 
Hospital General Universitario Gregorio Marañón, Madrid 
Hospital Universitari i Politècnic la Fe, Valencia 
Hospital Universitario Cruces, Baracaldo, Vizcaya 
Hospital Universitario Marqués de Valdecilla, Santander 
Hospital Universitario Miguel Servet, Zaragoza 
Hospital Universitario Virgen del Rocío, Seville 
Hospital Universitario General de Alicante, Alicante 
Hospital Universitario Reina Sofía de Córdoba, Córdoba 
Fundación Instituto Valenciano de Oncología (FIVO), Valencia 
Hospital Universiatario de Bellvitge, Barcelona 
Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria 
Hospital Universitario Ramón y Cajal, Madrid 
Hospital Universitario Virgen de Valme, Seville 
Hospital de la Santa Creu i Sant Pau, Barcelona 
Hospital Universitario 12 de Octubre, Madrid 
Hospital Universitari Vall d'Hebron, Barcelona 
Hospital Universitario Puerta del Mar, Cádiz 
 
Appendix Table 2. Characteristics of patients with localized and disseminated invasive fusariosis, Spain, 2000–2015* 
Neutropenia Neutropenic Nonneutropenic 
Variables Localized Disseminated p value† Localized Disseminated p value† 
Total 9 (100.0) 35 (100.0)  10 (100.0) 4 (100.0)  
Sex       
 M 6 (66.7) 20 (57.1) 0.72 6 (60.0) 2 (50.0) 1.00 
 F 3 (33.3) 15 (42.9) 0.72 4 (40.0) 2 (50.0) 1.00 
Median age, y (IQR) 45 (28–65) 47 (29–65) 0.81‡ 58 (26–79) 67 (56–79) 0.57‡ 
Treatment history (previous 30 d)       
 Antifungal 4 (44.4) 28 (80.0) 0.09 2 (20.0) 3 (75.0) 1.00 
 Corticosteroid 2 (22.2) 14 (40.0) 0.31 4 (40.0) 2 (50.0) 1.00 
Underlying conditions       
 Hematologic malignancy 8 (88.9) 33 (94.3) 0.51 3 (30.0) 2 (50.0) 0.58 
 Hematologic stem cell transplant 1 (11.1) 10 (28.6) 0.41 1 (10.0) 2 (50.0) 0.18 
 Graft-versus-host disease 1 (11.1) 3 (8.6) 0.56 0 1 (25.0) 0.29 
 Solid tumor 0 1 (2.9) 1.00 1 (10.0) 0 1.00 
 Other 1 (11.1) 1 (2.9) 0.37 6 (60.0) 2 (50.0) 1.00 
Clinical manifestations       
 Fever 8 (88.9) 32 (91.4) 1.00 4 (40.0) 4 (100) 0.09 
 Skin lesions 2 (22.2) 27 (77.1) <0.01 1 (10.0) 2 (50.0) 0.18 
 Lung involvement 3 (33.3) 29 (82.9) <0.01 5 (50.0) 4 (100) 0.22 
 Fungemia 3 (33.3) 18 (51.4) 0.46 4 (40.0) 1 (25.0) 1.00 
 Sinusitis 0 8 (22.9) 0.04 0 1 (25.0) 0.29 
 Blindness 0 4 (11.4) 0.57 0 0  
Concurrent infection 6 (66.7) 19 (54.3) 0.71 3 (30.0) 3 (75.0) 0.25 
*Values are no. (%), except where indicated. 
†p values obtained by Fisher exact test, except where indicated. 
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Appendix Table 3. Therapeutic regimens used to treat patients with invasive fusariosis, Spain, 2000–2015* 
Treatment Total Neutropenic Nonneutropenic p value† 
Total 58 (100.0) 44 (100.0) 14 (100.0)  
Monotherapy 36 (62.1) 24 (54.5) 12 (85.7) 0.04‡ 
Azole 17 (29.3) 8 (18.2) 9 (64.3) 0.002 
 Voriconazole 16 (27.6) 8 (18.2) 8 (57.1) 0.01‡ 
 Posaconazole 1 (1.7) 0 1 (7.1) 0.24 
Amphotericin B 19 (32.8) 16 (36.4) 3 (21.4) 0.35 
 Liposomal amphotericin B 17 (29.3) 14 (31.8) 3 (21.4) 0.52 
 Amphotericin B lipid complex 1 (1.7) 1 (2.3) 0 1.00 
 Amphotericina B deoxicholate 1 (1.7) 1 (2.3) 0 1.00 
Combined therapy 16 (27.6) 16 (36.4) 0 0.006 
 Liposomal amphotericin B plus voriconazole 13 (22.4) 13 (29.5) 0 0.03 
 Liposomal amphotericin B plus posaconazole 2 (3.4) 2 (4.5) 0 1.00 
 Amphotericin B lipid complex plus voriconazole 1 (1.7) 1 (2.3) 0 1.00 
Other§ 3 (5.2) 2 (4.5) 1 (7.1) 1.00 
Not treated 3 (5.2) 2 (4.5) 1 (7.1) 1.00 
*Values are no. (%), except where indicated. 
†p values obtained by Fisher exact test, except where indicated.  
‡Determined by χ2 test. 
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Appendix Figure 2. Probability of 90-day survival of patients with invasive fusariosis, Spain, 2000–2015. 
Log-rank test; p = 0.03. 
